Selected mechanisms of molecular resistance of Candida albicans to azole drugs

• Authors: Karolina Gołąbek , Joanna Strzelczyk , Aleksander Owczarek , Piotr Cuber , Anna Ślemp-Migiel , Andrzej Wiczkowski
• Languages of publication: EN

Abstracts

EN

A phenomenon of increasing resistance of Candida spp. to azoles has been observed for several years now. One of the mechanisms of lack of sensitivity to azoles is associated with CDR1, CDR2, MRD1 genes (their products are active transport pumps conditioning drug efflux from pathogen's cell), and ERG11 gene (encoding lanosterol 14α-demethylase). Test material was 120 strains of Candida albicans (60 resistant and 60 susceptible to azole drugs) obtained from clinical samples. The first stage of experiment assessed the expression of CDR1, CDR2, MDR1 and ERG11 genes by Q-PCR. The impact of ERG11 gene's mutations on the expression of this gene was analysed. The final stage of the experiment assessed the level of genome methylation of Candida albicans strains. An increase in the expression of CDR2, MDR1 and ERG11 was observed in azole-resistant strains of Candida albicans in comparison to strains sensitive to this class of drugs. Furthermore, 19 changes in the sequence of ERG11 were detected in tested strains. Four of the discovered mutations: T495A, A530C, G622A and A945C led to the following amino acid substitutions: D116E, K128T, V159I and E266D, respectively. It has also been found that statistically five mutations: T462C, G1309A, C216T, C1257T and A945C affected the expression of ERG11. The applied method of assessing the level of methylation of Candida albicans genome did not confirm its role in the development of resistance to azoles. The results indicate however, that resistance of Candida albicans strains to azole drugs is multifactorial.

Keywords

EN

Candida albicans; drug resistance; azoles

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2015
• Volume: 62
• Issue: 2
• Pages: 247-251

Dates

published

2015

received

2014-11-19

revised

2015-03-23

accepted

2015-03-24

(unknown)

2015-04-21

Contributors

author

Karolina Gołąbek

• Department of Medical and Molecular Biology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Zabrze, Poland

author

Joanna Strzelczyk

• Department of Medical and Molecular Biology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Zabrze, Poland

author

Aleksander Owczarek

• Statistical Division, Department of Instrumental Analysis, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia, Sosnowiec, Poland

author

Piotr Cuber

• Department of Parasitology, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia, Sosnowiec, Poland

author

Anna Ślemp-Migiel

• Laboratory of Microbiology in Hospital in Nowy Targ, Nowy Targ, Poland

author

Andrzej Wiczkowski

• Department of Medical and Molecular Biology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Zabrze, Poland

References

• Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM (2004) Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 48: 2124-2131.
• Cernicka J, Subik J (2006) Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis. Int J Antimicrob Agents 27: 403-408.
• Chen LM, Xu YH, Zhou CL, Zhao J, Li CY, Wang R (2010) Overexpression of CDR1 and CDR2 genes plays an important role in fluconazole resistance in Candida albicans with G487T and T916C mutations. J Int Med Res 38: 536-545.
• de Waard MA, Andrade AC, Hayashi K, Schoonbeek HJ, Stergiopoulos I, Zwiers LH (2006) Impact of fungal drug transporters on fungicide sensitivity, multidrug resistance and virulence. Pest Manag Sci 62: 195-207.
• Decottignies A, Goffeau A (1997) Complete inventory of the yeast ABC proteins. Nat Genet 15: 137-145.
• Del Sorbo G, Schoonbeek H, De Waard MA (2000) Fungal transporters involved in efflux of natural toxic compounds and fungicides. Fungal Genet Biol 30: 1-15.
• Ferreira AV, Prado CG, Carvalho RR, Dias KS, Dias AL (2013) Candida albicans and non-C. albicans Candida species: comparison of biofilm production and metabolic activity in biofilms, and putative virulence properties of isolates from hospital environments and infections. Mycopathologia 175: 265-272.
• Goldman GH, da Silva Ferreira ME, dos Reis Marques E, Savoldi M, Perlin D, Park S, Godoy Martinez PC, Goldman MH, Colombo AL (2004) Evaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis 50: 25-32.
• Lim CS, Rosli R, Seow HF, Chong PP (2012) Candida and invasive candidiasis: back to basics. Eur J Clin Microbiol Infect Dis 31: 21-31.
• Mishra NN, Prasad T, Sharma N, Payasi A, Prasad R, Gupta DK, Singh R (2007) Pathogenicity and drug resistance in Candida albicans and other yeast species. Acta Microbiol Immunol Hung 54: 201-235.
• Mishra PK, Baum M, Carbon J (2011) DNA methylation regulates phenotype-dependent transcriptional activity in Candida albicans. Proc Natl Acad Sci USA 108: 11965-11970.
• Morio F, Pagniez F, Besse M, Gay-andrieu F, Miegeville M, Le Pape P (2013) Deciphering azole resistance mechanisms with a focus on transcription factor-encoding genes TAC1, MRR1 and UPC2 in a set of fluconazole-resistant clinical isolates of Candida albicans. Int J Antimicrob Agents 42: 410-415.
• Morschhäuser J (2010) Regulation of multidrug resistance in pathogenic fungi. Fungal Genet Biol 47: 94-106.
• Neppelenbroek KH, Seó RS, Urban VM, Silva S, Dovigo LN, Jorge JH, Campanha NH. (2014) Identification of Candida species in the clinical laboratory: a review of conventional, commercial, and molecular techniques. Oral Dis 20: 329-344.
• Piddock LJ (2006) Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 19: 382-402.
• Sanglard D (2002) Clinical relevance of mechanisms of antifungal drug resistance in yeasts. Enferm Infecc Microbiol Clin 20: 462-469.
• Stanisz A (2006) Accessible statistics course using STATISTICA PL examples from medicine, In Basic Statistics, Vol I. Statsoft Poland, Kraków (in Polish).
• Strzelczyk JK, Slemp-Migiel A, Rother M, Gołąbek K, Wiczkowski A (2013) Nucleotide substitutions in the Candida albicans ERG11 gene of azole-susceptible and azole-resistant clinical isolates. Acta Biochim Pol 60: 547-552.
• Tyburski J, Studzińska A, Draca P, Tretyn A (2008) PCR in real time. The methods of data analysis. Biotechnologia 1: 86-96 (in Polish).
• Vázquez-González D, Perusquía-Ortiz AM, Hundeiker M, Bonifaz A (2013) Opportunistic yeast infections: candidiasis, cryptococcosis, trichosporonosis and geotrichosis. J Dtsch Dermatol Ges 11: 381-393.
• White TC, Marr KA, Bowden RA (1998) Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11: 382-402.
• Xu Y, Chen L, Li C (2008) Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations. J Antimicrob Chemother 61: 798-804.
• Yapar N (2014) Epidemiology and risk factors for invasive candidiasis Ther Clin Risk Manag 10: 95-105.

Identifiers

DOI

10.18388/abp.2014_940